Zynex Inc. (ZYXI) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for nonrecurring items. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on t ...

Revenue Growth - Device revenue increased by $2.2 million or 16% to $15.9 million for the three months ended June 30, 2024, compared to $13.7 million for the same period in 2023[234] - Net revenue increased by $4.9 million or 11% to $49.9 million for the three months ended June 30, 2024, from $45.0 million for the same period in 2023[237] - Net revenue for the six months ended June 30, 2024, increased by $9.3 million or 11% to $96.4 million from $87.1 million for the same period in 2023[237] - Growth in net revenue for the three and six months ended June 30, 2024, was primarily driven by a 20% and 21% increase in device orders, respectively[237] Supply Chain - Approximately 40% of supplies for electrotherapy products were sourced from three significant vendors for the six months ended June 30, 2024, compared to 26% from two vendors in the same period of 2023[236] Acquisitions - The Company acquired 100% of Kestrel Labs, Inc. in December 2021, which specializes in laser-based patient monitoring technology[229] - Kestrel's products, NiCO and HemeOx, are yet to be presented to the U.S. FDA for market clearance[229] Internal Controls - The Company has identified material weaknesses in internal control over financial reporting as of June 30, 2024[242] - Management concluded that the consolidated financial statements present fairly the financial position and results of operations in accordance with U.S. GAAP[123] - There were no changes in internal control over financial reporting that materially affected the controls during the quarter ended June 30, 2024[125]

Zynex Reports Second Quarter 2024 Financial Results ENGLEWOOD, Colo., July 25, 2024 -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2024. Key Second Quarter Highlights and Business Update Management Commentary "In the second quarter, increasing sales and profitab ...

Q2 2024 Revenue Increased 11% to $49.9 Million ENGLEWOOD, Colo., July 25, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2024. Key Second Quarter Highlights and Business Update Q2 2024 orders increased 20% year-over-year, the highest number of ...

Investor Relations Contact: Quinn Callanan, CFA or Brian Prenoveau, CFA MZ Group – MZ North America [email protected] +949 694 9594 ENGLEWOOD, Colo., July 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 25, 2024 at 4:15 PM Eastern Time to discuss its financial results for the second qu ...

ENGLEWOOD, Colo., July 11, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has been recognized for multiple awards by Top Workplaces and the U.S. News & World Report 2024-2025 ratings. Top Workplaces, the nation's most credible employer recognition program, has included Zynex in its 2024 Top Workplaces – Manufacturi ...

Zynex, Inc. (NASDAQ:ZYXI) Q1 2024 Earnings Conference Call April 30, 2024 4:15 PM ET Company Participants Quinn Callanan - CFA, Investor Relations Thomas Sandgaard - Chairman Of The Board, President & CEO Anna Lucsok - Chief Operating Officer Donald Gregg - President, Zynex Monitoring Solutions Dan Moorhead - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. And welcome to the Zynex First Quarter 2 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 Zynex, Inc. (Exact name of registrant as specified in its charter) | NEVADA | 90-0275169 | | --- | --- ...

Exhibit 99.1 Zynex Reports First Quarter 2024 Financial Results Q1 2024 Revenue Increased 10% to $46.5 Million ENGLEWOOD, Colo., April 30, 2024 -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non- invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2024. Key First Quarter Highlights and Business Update Management Comm ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 ZYNEX, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or org ...